



## Verzenio™ (abemaciclib) – Expanded indication

- On February 26, 2018, [Eli Lilly announced](#) the FDA approval of [Verzenio \(abemaciclib\)](#) tablets, for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
  - Previously, Verzenio was only approved for use in combination with [Faslodex® \(fulvestrant\)](#) for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; and as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
- The expanded indication approval for Verzenio was based on the MONARCH 3 study, a placebo-controlled trial involving 493 postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. Patients were randomized to receive an aromatase inhibitor plus either Verzenio or placebo. The primary endpoint was progression-free survival (PFS).
  - The median PFS in the Verzenio arm was 28.2 months vs. 14.8 months in the placebo arm (HR = 0.540 [95% CI: 0.418, 0.698, p < 0.0001]).
  - At the time of analysis, the overall survival data were immature and could not be reported.
- The recommended dose of Verzenio when used in combination with an aromatase inhibitor (or with Faslodex) is 150 mg orally twice daily until disease progression or unacceptable toxicity.
- The recommended dose of Verzenio when used as monotherapy is 200 mg orally twice daily until disease progression or unacceptable toxicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.